SEOUL, Sept. 26 (Yonhap) -- South Korea's health authorities said Thursday that they will suspend the manufacturing and sales of some ranitidine drug products that contain a probable human carcinogen.
The Ministry of Food and Drug Safety said a total of 269 ranitidine medicines contain N-nitrosodimethylamine (NDMA), a substance known to cause cancer, exceeding acceptable limits.
Ranitidine medicines decrease the amount of acid made in the stomach and are commonly used to treat stomach ulcers and heartburn, which is also called gastroesophageal reflux disease. One of the brand names of ranitidine here is Zantac.
The World Health Organization classifies NDMA as Group 2A, a probable human carcinogen. It is a known environmental contaminant and also found in water and foods.
The agency said it will form a committee to assess possible long-term effects on patients who have been taking ranitidine.
The agency also advises patients taking the products to discontinue use and talk to their doctors about safety concerns and other treatment options.
S. Korea's space program opens new chapter with rocket engine launch, satellites
Samsung aims to overcome biz hurdles through 180 tln won investment
Naver's relinquishing of news editing first step to addressing opinion rigging concerns
(News Focus) All eyes on Samsung's stock split, impact on share value
Samsung's stock split move to make it possible for ordinary investors to buy-sell shares